The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women °clinical correlation on 547 patients

The aims of this study were as follows: to confirm that the presence of estrogen (ER) and progesterone (PgR) receptors is an indicator of clinical behavior of human breast cancer independent of other known prognostic factors; to seek clinical correlates of those receptor values that best predict the...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1986-03, Vol.57 (6), p.1171-1180
Main Authors: Vollenweider‐Zerargui, Leila, Barrelet, Laurent, Wong, Yip, Lemarchand‐Béraud, Thérèse, Gómez, FULGENCIO
Format: Article
Language:English
Subjects:
Actuarial Analysis
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Breast Neoplasms - surgery
Cytosol - analysis
Female
Follow-Up Studies
Gynecology. Andrology. Obstetrics
Humans
Lymphatic Metastasis
Mammary gland diseases
Medical sciences
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Prognosis
Receptors, Estrogen - analysis
Receptors, Progesterone - analysis
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aims of this study were as follows: to confirm that the presence of estrogen (ER) and progesterone (PgR) receptors is an indicator of clinical behavior of human breast cancer independent of other known prognostic factors; to seek clinical correlates of those receptor values that best predict the overall disease evolution; and to determine the relative prognostic importance of PgR versus ER. The clinical records of 547 patients, the follow‐up of some extending to 6 years, were analyzed in retrospect. Patients were placed into one of four disease stages and also in three groups according to the degree of axillary node involvement. In each group the prognostic value of receptors for patient survival, disease‐free interval and, in case of metastasis or local recurrence, the response to endocrine treatment or chemotherapy were studied. The break point in the spectrum of receptor concentrations with regard to survival, disease‐free interval, and response to treatment was ≥20 for ER+, ≥15 for PgR+, and
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19860315)57:6<1171::AID-CNCR2820570618>3.0.CO;2-X